



(51) International Patent Classification:

C07K 14/55 (2006.01) *A61K 39/395* (2006.01)
C12N 15/26 (2006.01) *A61K 47/48* (2006.01)

(21) International Application Number:

PCT/EP2012/051991

(22) International Filing Date:

7 February 2012 (07.02.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

11153964.9 10 February 2011 (10.02.2011) EP
11164237.7 29 April 2011 (29.04.2011) EP

(71) Applicant (for all designated States except US): **ROCHE GLYCART AG** [CH/CH]; Wagistrasse 18, CH-8952 Schlieren (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **AST, Oliver** [DE/CH]; Jakob Spaltensteinstrasse 12, CH-8303 Bassersdorf (CH). **BRUENKER, Peter** [DE/CH]; Burgwiesenstrasse 3c, CH-8335 Hittnau (CH). **FREIMOSER-GRUNDSCHÖBER, Anne** [CH/CH]; Neunbrunnenstrasse 76, CH-8050 Zuerich (CH). **HERTER, Sylvia** [DE/CH]; Roosstrasse 76, CH-8105 Regensdorf (CH). **HOFER, Thomas U.** [CH/CH]; Buhnrain 8, CH-8052 Zuerich (CH). **HOSSE, Ralf** [DE/CH]; Schmiedstrasse 8, CH-6330 Cham (CH). **KLEIN, Christian** [DE/CH]; Chruezacherweg 41, CH-8906 Bonstetten (CH). **MOESSNER, Ekkehard** [DE/CH]; Felsenburgweg 5, CH-8280 Kreuzlingen (CH). **NICOLINI, Valeria G.** [ES/CH];

Sandfelsenstrasse 4, CH-8703 Erlenbach/ZH (CH). **UMANA, Pablo** [CR/CH]; Felsenrainstrasse 28, CH-8832 Wollerau (CH).

(74) Agent: **KLEIN, Thomas**; Grenzacherstrasse 124, CH-4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MUTANT INTERLEUKIN-2 POLYPEPTIDES

(57) Abstract: The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α -subunit of the IL-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant IL-2 polypeptides, polynucleotide molecules encoding the mutant IL-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant IL-2 polypeptides or immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

